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close to the Willingness to Pay threshold, Markov models should be analyzed with 
shorter cycle length or a DES approach adopted to ensure conclusions are robust.
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Objectives: To review the modeling-based economic evaluations (MB2E) of 
acetylcholinesterase inhibitors (ACE) and memantine (MEM) used in the field of 
Alzheimer’s disease (AD). MethOds: A systematic literature search was carried 
out based on several electronic databases such as Medline or the Cochrane Library 
up to November 2012. Modeling frameworks used to depict the natural history of 
AD and incorporation of treatment effects were qualitatively described and com-
pared. Results: More than thirty MB2E were identified with several local adapta-
tions based on ten original modeling frameworks. First published MB2E were either 
Markov state-transitions models or partition failure time survival models while 
most recent MB2E relied on discrete events simulations. The hallmark of the disease, 
the cognitive dimension, was first introduced to model the disease progression 
mainly based on the Mini Mental State Examination (MMSE) scale. The two other 
fundamental-functional and behavioral-dimensions were taken into account as 
a second step. Models relied on distinct clinical milestones and risk equations to 
extrapolate intermediate clinical endpoints from clinical trials (mainly on cognition 
and function) into long-term final endpoints. These latter were delay in severity, 
loss of patient autonomy, institutionalization, burden of care and quality-adjusted 
life years. Differences occurred as well on the way inter-patient heterogeneity was 
incorporated with a trend towards more micro-simulations technics. Eventually, 
predictors and inter-relations between the several dimensions of the natural history 
of the disease seemed not to be fully captured in the model structures with chal-
lenging needs to assess the resulting potential biases. cOnclusiOns: Advanced 
modeling methods in the field of AD were being introduced to better capture the 
continuous, progressive and multivariate natural history of AD. Further work is war-
ranted given the emerging early diagnosis technics, neuropathological biomarkers 
and targeting therapies.
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Objectives: Previous cost-effectiveness analyses of targeted therapies in meta-
static renal cell carcinoma (mRCC) have been based on randomised trials and 
evaluate just one single treatment-line. The aim of this study was to estimate 
the real-world cost-effectiveness of sequential first- and second-line treatments 
for patients with mRCC using a patient-level simulation (PLS) model. MethOds: 
Based on patient-level data from a Dutch population-based registry, a PLS model 
was developed that comprised entities (i.e. patients with mRCC), attributes 
assigned to the entities (i.e. prognostic factors), and events (i.e. second-line treat-
ment or death). Patients were repeatedly simulated from the model and time-to-
event was estimated using a lognormal distribution. A separate sampling process 
was used to determine which type of event occurred. Time to death following 
second-line treatment was modelled using a Weibull distribution. Lifetime health 
care costs were modelled using patient-level data from the registry. Results: In 
current daily practice, 50% (341/686) of patients did not receive any targeted ther-
apy and 42% (291/686) received sunitinib as first-line therapy. In the second line, 
31% (33/107) were treated with sorafenib and 31% (33/107) with everolimus. Mean 
overall survival (OS) was 13.6 months and mean costs were € 69,622 for all patients. 
In a strategy where all patients are treated according to clinical guidelines, mean 
OS was 15.2 months and costs were € 91,059. This meant an increase in OS (1.6 
months) and costs (€ 21,437) compared to current practice, with an incremental 
cost-effectiveness ratio of € 159,107 per life-year gained. Probabilistic sensitiv-
ity analyses showed the robustness of these results. cOnclusiOns: A complete 
disease model and real-world data are essential in estimating real-world cost-
effectiveness. Our PLS model allows comparisons between treatment strategies 
spanning multiple treatment lines, which will ultimately help to reveal the optimal 
strategy. For example, guidelines-based treatment appears to increase both OS and 
costs compared to current daily practice.
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Objectives: Long-term cardiovascular outcomes studies are routinely under-
taken to demonstrate safety in all new diabetes therapies. Given that diabetes 
models are extensively validated to contemporary outcomes trials they offer the 
potential to inform on design of new trials. The objective of this study was to 
use an established diabetes model to explore the relationship between levels 
of glycaemic control, major adverse cardiovascular events (MACE) and sample 
size. MethOds: The IMS CORE Diabetes Model (CDM) a validated and widely used 
simulation model was initiated with patient level data (PLD) drawn from NHANES. 
The model was run with a five-year time horizon and the sample sizes required 
to detect a difference in MACE (defined as myocardial infarction, stroke or CV 
death) at the 5% level as a function of change in HbA1c evaluated. Results: PLD 
from NHANES was available on 1853 subjects with mean (SD) age 63.6(12.1) years, 
53% male, duration of diabetes 9.6(8.5) years, baseline HbA1c 7.4% (1.8), systolic 
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Objectives: To evaluate cost-effectiveness of pneumococcal vaccination of 
children with 10-valent (PHiD-CV) compared with 13-valent pneumococcal con-
jugate vaccine (PCV-13). MethOds: A Markov cohort model which simulates in 
a Bulgarian birth cohort the disease process of invasive disease (ID) (meningitis 
and bacteremia), community acquired pneumonia (CAP), and acute otitis media 
(AOM) over life-time caused by S. pneumoniae and non-typeable Haemophilus 
Influenzae (NTHi). The cohort model essentially considers the perspective of the 
health care payer. Bulgarian specific epidemiological and demographic data and 
data from other country sources were obtained for the model. Base case assump-
tions include estimates of pneumococcal and NTHi infection rates as well as vaccine 
efficacy based on published literature, 94% vaccine coverage, herd protection and a 
(3+1) vaccination schedule. One-way sensitivity analyses performed to assess the 
impact of changes in key model assumptions. Results: PHiD-CV and PCV-13 are 
projected to prevent 29.4 and 29.9 cases of invasive diseases respectively and 437 
and 434 bacteremia hospitalizations respectively . PHiD-CV in comparison with 
PCV-13 is projected to prevent additional 9393 cases of AOM, 426 myringotomies 
and 2801 GP visits. Vaccinating a birth cohort with PHiD-CV is expected to gener-
ate 41 more QALYs compared to PCV-13. The estimated total savings for health 
care system are 1.77 mil Euro. The PHiD-CV is dominant in comparison with PCV-
13. Sensitivity analyses indicate that GP visits for AOM and efficacy vs. AOM due 
to Streptococcus Pneumonia non-Vaccine Types Sp nVT have biggest impact on 
results. cOnclusiOns: Overall, PHiD-CV is expected to have betterI impact and 
under the given assumptions, PHiD-CV dominates PCV-13 because it also has a 
larger cost offsets.
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Objectives: Analysing patient level data (PLD) within cost-effectiveness (CE) mod-
els offers the potential to better understand patient profiles associated with greatest 
health economic benefit. The objective of this study was to contrast the application 
of average treatment efficacy profiles compared to patient level treatment efficacy in 
assessing the CE of insulin glargine (IG) versus Neutral protamine Hagedorn (NPH) in 
Type 2 diabetes mellitus (T2DM) MethOds: This study used the IMS Core Diabetes 
Model (CDM), a validated and established diabetes model to evaluate the CE of 
switching to IG from NPH using published effectiveness data from a large population 
based cohort. Average HbA1c reduction after switching from NPH was -0.18% and 
weight gain was 0.5kg. Annual diabetes specific therapy cost was £573 (IG) versus 
£320 (NPH). A PLD extract was obtained from NHANES and the CE of IG versus NPH 
assessed applying (a) overall mean treatment effects (MTE) and (b) baseline HbA1c, 
BMI and sex adjusted treatment effects (ATE). Costs (2012 UK£) and benefits were 
discounted at 3.5%. Results: For the MTE and ATE scenarios, the incremental cost 
effectiveness ratio (ICER) was £28,925 and £57,279 respectively. For MTE scenario, 
765 (41.1%) of subjects were CE at the £20,000 willingness to pay (WTP) and 47 IG 
subjects (6.1%) were both cost saving with increased health benefit. Using ATE, 
525 (28.2%) were CE at the £20,000 WTP threshold with 164 (31.2%) of IG subjects 
identified as both cost saving with increased health benefit. The odds ratio (OR) of 
being both cost saving with greater health benefit was significantly associated with 
age, OR= 0.89(0.87-0.93) and baseline HbA1c, OR= 6.11 (4.64-8.03). cOnclusiOns: 
The identification of patient characteristics associated with greater potential for 
health gain and reduced cost is an important goal. The analysis of PLD alongside 
simulation model output provides an additional mechanism for informing health 
care decision-making.
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Objectives: To assess the bias introduced to absolute costs, absolute QALYs and 
the incremental cost effectiveness ratio (ICER) associated with Markov models, 
compared with discrete event simulation (DES) models. To investigate how such 
biases are a function of cycle length and half-cycle correction. MethOds: A hypo-
thetical three health state model was constructed using both Markovian and DES 
approaches. Costs and utility were assigned to each health state and the ICERs 
between two treatment strategies were estimated. Six Markov models using dif-
ferent cycle lengths (1 month, 3 month, 1 year), and with and without half cycle 
correction were constructed. Differences in the absolute costs and QALYs generated 
between each Markov model were compared with the DES approach and the ICERs 
generated by each model were compared. Results: Markov model simulation was 
shown to introduce biases in the absolute costs and QALYs when compared with a 
DES approach. The bias was related to the duration of the time cycle with the results 
converging to the DES values as the time cycle was reduced. The initial bias in cost 
fell from 14% to less than 1%; QALY bias was consistently below 1%. The ICERs show 
bias between 2.4% and 9.6% when using a 1 year cycle and between 0.6% - 5.4% when 
using a 1 month cycle. The half-cycle correction reduced absolute bias between 2% 
- 10%, the ICERs were not affected. The time cycle duration was the primary param-
eter in reducing bias. cOnclusiOns: Markov models introduce bias due to the 
simplifying assumptions of fixed cycle length and half cycle correction; DES models 
do not suffer the same biases. It is suggested that when the ICERs produced are 
